We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Newly Identified Biomarker Indicates Risk of Breast Cancer Bone Metastasis

By LabMedica International staff writers
Posted on 28 Sep 2015
Print article
Image: Top, breast cancer tumor cells negative for the bone metastasis marker, MFA. Bottom, breast cancer tumor cells positive for the marker (Photo courtesy of Gomis Laboratory, Institute for Research in Biomedicine, Barcelona).
Image: Top, breast cancer tumor cells negative for the bone metastasis marker, MFA. Bottom, breast cancer tumor cells positive for the marker (Photo courtesy of Gomis Laboratory, Institute for Research in Biomedicine, Barcelona).
Cancer researchers have identified a gene that is critically linked to the ability of some breast cancer tumors to metastasize to the bone and which may be developed into a biomarker to identify patients at risk for this development.

There are currently no biomarkers for early breast cancer patient populations at risk of bone metastasis, which occurs in about 15%–20% of patients with estrogen-receptor-positive breast tumors. These tumors tend to metastasize to the bone, and represent 80% of all breast cancers.

Investigators at the Institute for Research in Biomedicine (Barcelona, Spain) analyzed more than 900 clinical samples of primary breast tumors while looking for genetic variations that favored bone metastasis.

They reported in the September 15, 2015, online edition of the Journal of the National Cancer Institute that patients with tumors in which the MAF (v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog) gene was altered had a risk of metastasis to the bone that was 14 times higher than in those patients in which the gene was unaltered.

"This gene reliably predicts metastasis to the bone. Studying whether it is highly expressed in breast cancer patients to determine whether this also happens in a clinical setting is an important next step. It could improve the quality of life of these patients and the way clinicians manage their cancer. And this is exactly what we are doing," said senior author Dr. Roger Gomis, oncology group leader at the Institute for Research in Biomedicine.

The findings obtained in this study have led to the creation of the company Inbiomotion (Barcelona, Spain), which has developed the tools necessary to begin clinical trials. An initial clinical trial will validate the use of the marker in some 3,300 patients.

Related Links:

Institute for Research in Biomedicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more


view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.